trial

Effect of Curcumin Add-On Therapy on Quality of Life and IL-1β Levels in Patients With Schizophrenia

NCTId NCT07523256
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 44 (actual)
Sponsored by Rinvil Renaldi
Primary completion 2026-01-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
44 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2025-11-01
Primary completion
2026-01-31
Eligibility
MALE · 20 Years · 45 Years

Interventions & indications

Drugs
CurcuminRisperidone

Sponsors

Rinvil RenaldiLead Sponsor

Sites

1 total
Makassar, Indonesia

Facts & assertions

4 sourced
Enrollment
44
Phase
NA
Primary Completion Date
2026-01-31
Status
COMPLETED
relationships
The graph out of here
drug
Curcumin
drug
Risperidone
drug
lead_sponsor
Rinvil Renaldi
company
indication
Psychotic Disorders
indication
Psychotic Disorders
indication
Schizophrenia
indication